Stevanato Group S.p.A. (STVN)
NYSE: STVN · Real-Time Price · USD
20.15
+0.35 (1.77%)
Jul 28, 2026, 4:00 PM EDT - Market closed
Stevanato Group Financials Overview
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,203 | 1,186 | 1,104 | 1,085 | 983.68 | 843.92 |
Revenue Growth | 6.99% | 7.45% | 1.72% | 10.34% | 16.56% | 27.47% |
Gross Profit Gross Profit Growth | 349.16 | 343.88 | 302.32 | 339.89 | 319.8 | 265.41 |
Operating Income Operating Income Growth | 202.93 | 198.8 | 161.14 | 200.72 | 192.43 | 162.23 |
Net Income Net Income Growth | 141.39 | 139.83 | 117.77 | 145.69 | 143.02 | 134.27 |
Earnings Per Share EPS Growth | 0.51 | 0.51 | 0.43 | 0.55 | 0.54 | 0.53 |
EPS Growth | 8.51% | 18.61% | -21.82% | 1.85% | 1.89% | 60.61% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '25 Jun 30, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Biopharmaceutical and Diagnostic Solutions Biopharmaceutical and Diagnostic Solutions Growth | 976.82 | 1,038 | 933.74 | 879.29 | 799.65 | 694.04 |
Engineering Engineering Growth | 168.28 | 148.11 | 170.29 | 206.07 | 184.03 | 149.88 |
Revenue (Total) Revenue (Total) Growth | 1,145 | 1,186 | 1,104 | 1,085 | 983.68 | 843.92 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 111.67 | 130.6 | 98.27 | 69.6 | 228.74 | 411.04 |
Total Debt Total Debt Growth | 452.09 | 470.87 | 434.61 | 398.92 | 219.16 | 248.49 |
Net Cash (Debt) Net Cash Growth | -340.42 | -340.27 | -336.34 | -329.31 | 9.58 | 162.55 |
Net Cash Growth | - | - | - | - | -94.11% | - |
Net Cash Per Share Net Cash Per Share Growth | -1.25 | -1.25 | -1.24 | -1.24 | 0.04 | 0.64 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 186.2 | 286.08 | 155.78 | 105.21 | 103.31 | 133.34 |
Capital Expenditures CapEx Growth | - | -263.76 | -302.6 | -433.23 | -235.03 | -107.69 |
Free Cash Flow Free Cash Flow Growth | 186.2 | 22.32 | -146.82 | -328.02 | -131.72 | 25.65 |
Free Cash Flow Growth | 1.18% | - | - | - | - | -61.20% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 29.02% | 28.99% | 27.38% | 31.32% | 32.51% | 31.45% |
Operating Margin | 16.86% | 16.76% | 14.60% | 18.49% | 19.56% | 19.22% |
Pretax Margin | 16.06% | 15.94% | 14.52% | 17.46% | 19.08% | 19.63% |
Profit Margin | 11.75% | 11.79% | 10.67% | 13.42% | 14.54% | 15.91% |
FCF Margin | 15.47% | 1.88% | -13.30% | -30.22% | -13.39% | 3.04% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.062 | - | 0.054 | 0.053 | 0.054 | 0.051 |
Dividend Per Share Growth | 1.13% | - | 1.89% | -1.85% | 5.88% | -99.98% |
Dividend Yield | 0.31% | 0.31% | 0.25% | 0.22% | 0.30% | 0.22% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 34.27 | 33.62 | 48.70 | 44.88 | 31.02 | 37.25 |
Forward PE | 27.79 | 29.61 | 38.13 | 39.60 | 32.31 | 45.63 |
P/FCF Ratio | 2296.08 | 209.74 | - | - | - | 203.78 |
PS Ratio | 3.97 | 3.95 | 5.18 | 6.04 | 4.51 | 6.19 |